chartexchange

The Precision Peptide Company Begins Development of GLP3 Patch, Its Fourth Needle-Free Peptide

Newsfile | Oct 20, 2026 7:00 AM EDT

Needle-free line grows to four U.S.-made patches in a peptide market projected to reach US$87.21 billion by 2035 1HighlightsGLP3 transdermal patch enters development in the United States, the fourth product in the Company's needle-free peptide patch lineGLP3 is the Company's second patch in the metabolic and weight-management category, following tirzepatideThe Recovery Patch (BPC-157) is on sale now; 20,000 Thymosin Alpha-1 patches ("TA1") ordered, with delivery expected in January 2027No...

Read original article